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Mutations in the amyloid precursor protein
(APP) cause early-onset Alzheimer’s disease
(AD), but the only genetic risk factor for late-
onset AD is the 34 allele of apolipoprotein E
(apoE), a major cholesterol carrier. Using Cre-
lox conditional knockout mice, we demonstrate
that lipoprotein receptor LRP1 expression reg-
ulates apoE and cholesterol levels within the
CNS. We also found that deletion of APP and
its homolog APLP2, or components of the g-
secretase complex, significantly enhanced the
expression and function of LRP1, which was re-
versed by forced expression of the APP intra-
cellular domain (AICD). We further show that
AICD, together with Fe65 and Tip60, interacts
with the LRP1 promoter and suppresses its
transcription. Together, our findings support
that the g-secretase cleavage of APP plays
a central role in regulating apoE and cholesterol
metabolism in the CNS via LRP1 and establish
a biological linkage between APP and apoE,
the two major genetic determinants of AD.
INTRODUCTION
Mounting genetic and biochemical evidence strongly
supports the hypothesis that amyloid b-peptide (Ab)
accumulation in the brain is an early and toxic event in
the pathogenesis of Alzheimer’s disease (Hardy and
Selkoe, 2002). Accordingly, reducing brain Ab production
and/or increasing its clearance have become attractive66 Neuron 56, 66–78, October 4, 2007 ª2007 Elsevier Inc.targets for AD drug development (Hardy and Selkoe,
2002). Ab is derived from sequential proteolytic process-
ing of amyloid precursor protein (APP), a ubiquitously ex-
pressed type I transmembrane protein that undergoes
two distinct processing pathways (Selkoe and Kopan,
2003; Zheng and Koo, 2006). In the nonamyloidogenic
pathway, APP undergoes ectodomain shedding by a-
secretase, identified as members of the ADAM metallo-
protease family (Zheng and Koo, 2006). Subsequent
cleavage of the APP C-terminal membrane-associated
stub by g-secretase (Selkoe and Kopan, 2003) generates
a nontoxic p3 peptide, as well as the APP intracellular do-
main (AICD) (Selkoe and Kopan, 2003). In the amyloido-
genic pathway, APP is first cleaved by the b-secretase
b-site APP cleaving enzyme 1 (BACE1) (Vassar et al.,
1999) and then by g-secretase to generate Ab and
AICD. Mutations associated with early-onset familial
forms of AD (FAD) are found in the APP gene itself or in
the genes of presenilin 1 (PS1) and PS2, whose products,
along with nicastrin, Pen-2, and Aph-1, are obligate com-
ponents of a multiprotein complex that gives rise to g-
secretase activity (Selkoe and Kopan, 2003). A common
feature of all FAD mutations is that they increase the gen-
eration of Ab peptides or the proportion of the longer
Ab42 form, considered to be more amyloidogenic and
pathogenic than the shorter Ab40 due to its highly aggre-
gative nature (Hardy and Selkoe, 2002).
Although FAD genetics and mouse models have gen-
erated tremendous insights into AD pathogenesis, the
vast majority of AD cases are sporadic with late-onset.
A major genetic risk factor that was initially discovered
in 1993 and has since been validated in numerous
genetic studies is the presence of the 34 allele of the apo-
lipoprotein E (APOE) gene (Corder et al., 1993). ApoE is
a major apolipoprotein in the brain and exists in three
isoforms in humans (apoE2, apoE3, apoE4), each differ-
ing by a single amino acid (Mahley, 1988). In the brain,
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APP Regulates Brain apoE MetabolismapoE/lipoprotein particles are produced primarily by
astrocytes and are believed to deliver cholesterol and
other lipids to neurons via lipoprotein receptors, namely
members of the low-density lipoprotein receptor (LDLR)
family (Herz and Bock, 2002; Herz and Chen, 2006).
Although the mechanisms underlying the pathogenic
nature of apoE4 in sporadic AD are still poorly un-
derstood, several models have been proposed and
supported by in vitro and in vivo studies. First, apoE
interacts with Ab, and apoE4 likely possesses greater
ability to promote Ab fibrillogenesis and amyloid plaque
formation (Holtzman et al., 2000). Second, apoE facili-
tates Ab clearance via apoE receptors expressed either
in neurons (Zerbinatti and Bu, 2005) or in the blood-brain
barrier (Zlokovic, 2005). ApoE4 is less functional in Ab
clearance owing to its weaker affinity to Ab (LaDu
et al., 1994). Third, apoE4 may be toxic to neurons inde-
pendently of Ab aggregation and clearance (Huang,
2006). It is possible that multiple pathways contribute
to the pathogenic nature of apoE4 in AD.
Cholesterol is an essential component of membranes
and myelin sheathes and is crucial for synaptic integrity
and neuronal functions (Pfrieger, 2003). Interestingly, an
Figure 1. APP Regulates ApoE and Cholesterol Metabolism
(A and B) ApoE levels were decreased and cholesterol content was
increased in the absence of APP or APP/APLP2. ApoE and cholesterol
levels weremeasured in triplicates in lysates ofWT,APP-KO, andAPP/
APLP2-DKOMEF cells, normalized against total protein and plotted as
a percentage of WT controls.
(C and D) ApoE levels were also decreased and cholesterol content in-
creased in brain lysates of APP-KO and APP/APLP2-DKOmice. ApoE
and cholesterol levels were measured in brain lysates of WT, APP-KO,
and APP/APLP2-DKO mice (n = 4), normalized against total protein
and plotted as a percentage of WT controls.
Data represent mean ± SEM; N.S., not significant; *p < 0.05.association between brain cholesterol metabolism and
the risk of AD has been proposed (Shobab et al., 2005).
Early studies indicated that the use of statins, which inhibit
cholesterol synthesis, is associated with a significant
decrease in AD prevalence; however, several recent
prospective studies do not support such a conclusion
(Shobab et al., 2005). Additionally, the effect of cholesterol
on the amyloidogenic processing of APP to Ab remains
controversial (Ledesma and Dotti, 2006). Intriguingly,
apoE4 knockin mice exhibit decreased brain cholesterol
levels even though the peripheral cholesterol levels are
increased (Hamanaka et al., 2000). A reduction of brain
cholesterol levels is also observed in AD brains (Ledesma
and Dotti, 2006). These disparate findings raise the need
for an understanding of brain cholesterol metabolism
and its potential dysregulation in AD.
In this manuscript, we present a linkage between APP
processing and apoE/cholesterol metabolism. Specifi-
cally, we found that lack of either APP/APLP2 or PS1/
PS2 leads to increased brain apoE/cholesterol catabo-
lism. We show that the APP processing product,
AICD, suppressed expression of the major apoE/lipo-
protein receptor LRP1 by binding directly to its pro-
moter following association with the adaptor protein
Fe65. Defective apoE/cholesterol catabolism in APP/
APLP2 and PS1/PS2 knockout cells was restored by
a forced expression of AICD. Together, our results re-
veal a biological function of APP in the regulation of
brain apoE and cholesterol metabolism, offering new
alternatives for the design of therapeutic strategies to
treat AD.
RESULTS
APP and APLP2 Regulate Brain ApoE
and Cholesterol Metabolism
APP processing and apoE/cholesterol metabolism are
two important events in the pathogenesis of AD. To exam-
ine whether these two pathways are functionally related,
we analyzed cellular apoE and cholesterol levels in mouse
embryonic fibroblasts (MEFs) of WT, APP-KO, or APP and
APLP2 double-knockouts (APP/APLP2-DKO). To mini-
mize potential clonal effects when MEF cells were estab-
lished, APP-KO MEF cells stably retransfected with
APP695 cDNA were used as WT controls. The APP-KO
and APP/APLP2-DKO cells displayed a significant
decrease in apoE levels and a concomitant increase in
cholesterol levels compared to WT controls (Figures 1A
and 1B). The apoE and cholesterol levels we measured
likely reflect a combination of those derived from both
serum and cells. One possible explanation of these find-
ings is that lack of APP or APP/APLP2 leads to increased
catabolism of apoE/lipoprotein, resulting in increased
intracellular cholesterol levels (Mahley, 1988). To assess
whether these changes also occur in vivo, we compared
brain apoE and cholesterol levels in WT, APP-KO, and
APP/APLP2-DKO mouse brain. ApoE levels were de-
creased by 50% in APP-KO and further decreased inNeuron 56, 66–78, October 4, 2007 ª2007 Elsevier Inc. 67
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APP Regulates Brain apoE MetabolismFigure 2. APP/APLP2 Regulates LRP1
Expression and Function
(A) LRP1 and LDLR expression levels were
compared between WT, APP-KO, and APP/
APLP2-DKO MEF cells by western blot. Equal
amount of protein in this and subsequent fig-
ures was loaded to each lane.
(B) Densitometric analyses of western blots
from triplicate samples demonstrate a signifi-
cant increase in the expression of LRP1, but
not LDLR, in the absence of APP/APLP2.
(C) LRP1 and LDLR mRNA levels were quanti-
fied in WT, APP-KO, and APP/APLP2-DKO
MEF cells by real-time PCR. LRP1 mRNA, but
not LDLR mRNA, was significantly increased
in the absence of APP/APLP2.
(D) 125I-a2M (1nM)binding toWT,APP-KO, and
APP/APLP2-DKO MEF cells was performed at
4C for 1 hr in the absence or presence of
RAP (500 nM). RAP-inhibitable 125I-a2M bind-
ingwas normalized against total cellular protein
and plotted as a percentage of WT controls.
(E) 125I-a2M (1 nM) uptake and degradation
assays were performed at 37C for 4 hr in the
absence or presence of RAP (500 nM). RAP-
inhibitable 125I-a2M degradation was normal-
ized against total cellular protein and plotted
as a percentage of WT controls.
(F) LRP1 and LDLR expression levels in the brain were compared between WT, APP-KO, and APP/APLP2-DKO newborn mice by western blot.
(G)Densitometric analysesofwesternblots (n=3) indicate a significant increase in theexpression of LRP1, but not LDLR, in theabsenceofAPPorAPP/
APLP2.
(H) LRP1 and LDLR mRNA levels were quantified in the brain of WT, APP-KO, and APP/APLP2-DKO newborn mice (n = 3) by real-time PCR. LRP1
mRNA, but not LDLR mRNA, was significantly increased in the absence of APP/APLP2.
(I) LRP1 expression in the brain was compared bywestern blot betweenWTandAPP-KOmice at 4months of age. Similar increase in LRP1 expression
was observed in adult APP-KO mouse brain.
Data represent mean ± SEM; N.S., not significant, *p < 0.05; **p < 0.01.APP/APLP2-DKO when compared to WT littermate
controls (Figure 1C). A corresponding increase in choles-
terol levels was also observed in APP-KO and APP/
APLP2-DKO mouse brain when compared to WT controls
(Figure 1D). Together, these results raise the possibility
that apoE and cholesterol levels are modulated, either
directly or indirectly, by APP and APLP2 and/or their pro-
cessing products.
APP and APLP2 Regulate LRP1 Expression
and Function
The increased catabolism of apoE/lipoprotein by APP-KO
and APP/APLP2-DKO cells leads us to investigate the
possibility that apoE receptor levels maybe upregulated
in these cells. To test this possibility, we compared ex-
pression levels of two major brain apoE receptors, LRP1
and LDLR (Herz and Bock, 2002), in WT, APP-KO, and
APP/APLP2-DKO MEF cells. Western blotting using two
different antibodies to LRP1 showed that LRP1 levels
were significantly increased in APP-KO MEF cells and in
APP/APLP2-DKO MEF cells compared to WT MEF cells
(Figures 2A and 2B). The expression of the LDLR was
not altered by APP/APLP2 deletion (Figures 2A and 2B).
To analyze whether changes in LRP1 expression were at
the transcriptional or posttranscriptional level, we com-
pared LRP1 mRNA levels by real-time PCR. As shown in68 Neuron 56, 66–78, October 4, 2007 ª2007 Elsevier Inc.Figure 2C, LRP1mRNA levels were significantly increased
in both APP-KO and APP/APLP2-DKO MEF cells when
compared to WT control cells. To investigate whether
changes in LRP1 expression also correlate with changes
in LRP1 function, we analyzed binding and endocytosis
of a2-macroglobulin (a2M), a high-affinity ligand for
LRP1 (Herz and Bock, 2002). Ligand-binding assays using
125I-a2M demonstrated increased binding capacity in
APP-KO and APP/APLP2-DKO MEF cells when com-
pared to WT control cells (Figure 2D). Similar increase
was seen when 125I-a2M uptake and degradation were
analyzed (Figure 2E).
To examine whether our in vitro findings were repro-
duced in vivo, we compared LRP1 expression in the brains
of newborn APP-KO, APP/APLP2-DKO, and littermate
control mice. LRP1 expression, but not LDLR expression,
was significantly increased in APP-KO and APP/APLP2-
DKO mouse brains when compared to WT controls both
at the protein (Figures 2F and 2G) and mRNA levels
(Figure 2H). Similar increase in LRP1 expression was
also observed in the brain of APP-KO mice at 4 months
of age. These results demonstrate that LRP1 expression
and function are modulated by APP/APLP2 or their pro-
cessing products and suggest that APP/APLP2 likely
modulate brain apoE and cholesterol metabolism via
regulation of LRP1 levels.
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APP Regulates Brain apoE MetabolismFigure 3. LRP1 Is Essential for Brain
ApoE and Cholesterol Metabolism
(A) LRP1 expression in the forebrain was eval-
uated in LRP1 forebrain knockout (LRP1-KO)
and WT littermate control mice by western
blot using two distinct LRP1 antibodies
(against 515 kDa subunit and 85 kDa subunit,
respectively). Equal amount of protein in this
and subsequent figures was loaded to each
lane.
(B) Densitometric quantification of LRP1 ex-
pression was performed as described in Ex-
perimental Procedures from two independent
experiments (n = 4).
(C) Double immunofluorescence staining using
an LRP1 antibody (detected with Alexa 488,
green) and neuronal marker NeuN antibody
(detected with Alexa 633, red). Shown are
representative staining in CA1 neurons and
pyramidal neurons of frontal cortex. Note that
LRP1 expression was almost absent in these
forebrain neurons.
(D) APP-FL and APP-CTF levels were compared by western blot between WT and LRP1-KO MEF cells.
(E) APP-FL and APP-CTF levels were compared by western blot between WT and LRP1-KO mouse brains.
(F and G) ApoE and cholesterol levels in the brain were compared between LRP1-KO andWT controls (n = 4). ApoE levels were significantly higher (F),
and cholesterol levels were significantly lower (G) in LRP1-KO mice.
Data represent mean ± SEM; *p < 0.05, **p < 0.01.LRP1 Modulates Brain ApoE/Lipoprotein
Metabolism
LRP1 is abundantly expressed in the brain, but in vivo
evidence that LRP1 regulates brain apoE and cholesterol
metabolism is lacking. Because conventional knockout
of LRP1 is early embryonic lethal (Herz et al., 1992), we
generated conditional LRP1 forebrain knockout mice by
crossing LRP1 floxP mice (Rohlmann et al., 1998) with
aCamKII-Cre mice (Tsien et al., 1996). LRP1 expression
was significantly decreased in the forebrain as determined
by immunobloting using antibodies directed against either
the 515 kDa subunit or the 85 kDa subunit (Figures 3A and
3B). Remaining LRP1 expression detected by western
blotting likely represents expression inglial cells (Moestrup
et al., 1992). By double immunofluorescence staining us-
ing LRP1-specific antibody and NeuN antibody, we con-
firmed that LRP1 expression was nearly abolished in CA1
neurons of the hippocampus and in pyramidal neurons of
the frontal cortex (Figure 3C). To examine howan LRP1de-
letion affects APP levels andprocessing,wecompared the
steady-state levels of the full-lengthAPPandAPPC-termi-
nal fragment (CTF). We found that deletion of LRP1 slightly
increased the steady-state levels of full-length APPwhile it
decreased the levels of APP-CTF both in LRP1-KO MEF
cells (Figure 3D) and in mouse brain (Figure 3E), likely
reflecting a stabilization of APP at the cell surface due to
reduced endocytosis (Cam et al., 2005).
To evaluate the impact of LRP1 deletion on apoE and
cholesterol metabolism, we compared apoE and choles-
terol levels in the forebrain of LRP1-KO and WT littermate
controls. We found that while apoE levels were signifi-
cantly increased (Figure 3F), cholesterol levels were
decreased (Figure 3G) in the LRP1-KO mice, suggestingimpaired catabolism of apoE/lipoprotein particles. The
changes in apoE and cholesterol levels in the absence of
LRP1 were also observed in LRP1-KO MEF cells (Figures
4A and 4B). Interestingly, the half-life of apoE is signifi-
cantly increased in LRP1-KO MEF cells (Figure 4C), sug-
gesting that in the absence of LRP1, apoE catabolism is
decreased. ApoE mRNA levels were not changed
between WT and LRP1-KO MEF cells or brain tissues
(data not shown). Further, apoE mRNA levels were not
changed between WT and APP-KO and APP/APLP2-
DKO MEF cells (Figure 4D) or brain tissues (Figure 4E).
Together, these results demonstrate that LRP1 is a bona
fide apoE/lipoprotein receptor that modulates apoE and
cholesterol metabolism in the brain.
Ab Is Not Required for LRP1 Regulation
A recent study demonstrated a role for Ab in regulating the
biosynthesis of cholesterol and sphingomyelin (Grimm
et al., 2005). Therefore, we evaluated the possibility that
Ab may be the processing product of APP that regulates
LRP1 expression levels. Because b-secretase BACE1 is
necessary for Ab production (Luo et al., 2001), we evalu-
ated the effects of BACE1 knockout on LRP1 expression.
Deficiency of BACE1 in either MEF cells or in mouse brain
did not alter LRP1 expression or function (see Figure S1 in
the Supplemental Data available with this article online).
Furthermore, no difference in LRP1 expression was found
in MEF cells overexpressing a human APP bearing the Ab-
overproducing Swedishmutation (APPsw) in either theWT
background (high Ab levels) or BACE1-KO background
(no Ab) (Figure S1). These results indicate that Ab produc-
tion is not required for LRP1 regulation.Neuron 56, 66–78, October 4, 2007 ª2007 Elsevier Inc. 69
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APP Regulates Brain apoE MetabolismFigure 4. Absence of LRP1 Expression
Increases ApoE Half-Life
(AandB)ApoE(A)andcholesterol (B) levelswere
measured in triplicate in lysates of WT and
LRP1-KO MEF cells, normalized against total
protein and plotted as a percentage ofWT con-
trols.
(C)WTand LRP1-KOMEFcellswere incubated
with serum-free medium for 2 hr and chased in
the presence of protein synthesis inhibitor cy-
cloheximide for0,1,2,or4hr.ApoE levelsunder
each condition were measured by ELISA and
plotted against chase time. Note apoE half-life
is significantly increased inLRP1-KOMEFcells.
(D and E) ApoE mRNA was quantified by real-
time PCR in WT, APP-KO, and APP/APLP2-
DKO MEF cells (D) or brain tissues (E). Note
apoE mRNA levels were not significantly
affected by APP/APLP2 deletion.
Data represent mean ± SEM; N.S., not signifi-
cant; *p < 0.05.g-Secretase Activity Regulates LRP1 Expression
and Function
Following a- or b-cleavage, the C-terminal stub of APP is
processed by g-secretase to generate AICD, which has
been previously reported to translocate to the nucleus
and regulate gene transcription (Baek et al., 2002; Cao
and Sudhof, 2001; Pardossi-Piquard et al., 2005). To
examine whether g-secretase cleavage is required for
APP-mediated regulation of LRP1 expression, we first
compared LRP1 expression in WT MEF cells to those
lacking presenilin (PS), an essential component of the
g-secretase complex. Western blotting showed that
LRP1 expression was significantly increased in PS1/2
double-knockout (PS-DKO) MEF cells (Figures 5A and
5B) when compared to WT MEF cells, while the expres-
sion of the LDLR was not affected. A similar increase in
LRP1 expression was seen in PS1-KO MEF cells
(Figure S2). Real-time PCR analysis confirmed an increase
in LRP1 expression at the mRNA levels (Figure 5C and
Figure S2). PS-DKO MEF cells also showed increased
binding and degradation of the LRP1 ligand 125I-a2M
when compared to WT MEF cells (Figures 5D and 5E
and Figure S2). To test whether LRP1 expression was
altered in the absence of the g-secretase function in
vivo, brain tissues from PS-DKO, PS1-KO, and their litter-
mate controls were analyzed for LRP1 expression by
western blotting and real-time PCR. The loss of g-secre-
tase function in PS-DKOmouse brains was demonstrated
by an accumulation of APP-CTF, a substrate for g-secre-
tase (Figure 5F). We found that expression of LRP1 was
significantly increased in PS-DKO (Figures 5F–5H) and
PS1-KO (Figure S2) mouse brains.
The requirement of g-secretase activity in LRP1 regula-
tion was further verified by two alternative approaches.
MEF cells lacking nicastrin, another essential component
of the g-secretase complex (Selkoe and Kopan, 2003),
also showed increased LRP1 expression and function
compared to WT control MEF cells (Figure S3). Further-70 Neuron 56, 66–78, October 4, 2007 ª2007 Elsevier Inc.more, treatment with three distinct g-secretase inhibitors
(L685,458, DAPT, DFK) enhanced LRP1 expression in
WT MEF cells (Figures 5I and 5J). Together, our results
demonstrate that g-secretase activity regulates LRP1
expression and function both in vitro and in vivo.
AICD Rescues LRP1 Expression in the Absence
of APP/APLP2 or PS Expression
To directly address whether the g-secretase product,
AICD, is involved in LRP1 regulation, we first analyzed
the effects of AICD forced expression on LRP1 expres-
sion. Transient transfection of AICD into U87 cells signifi-
cantly suppressed LRP1 expression without affecting
LDLR levels (Figures 6A and 6B). The adaptor protein
Fe65 has been previously shown to modulate AICD stabil-
ity and potentiate its subsequent nuclear translocation
(Cao and Sudhof, 2001). When overexpressed in U87
cells, Fe65 alone slightly suppressed LRP1 expression;
however, coexpression of Fe65 with AICD further
enhanced the AICD-mediated suppression of LRP1 ex-
pression (Figures 6A and 6B).
BACE1 cleavage of APP followed by g-secretase cleav-
age generates Ab40 or Ab42 with concomitant production
of AICD consisting of either 59 or 57 amino acids, respec-
tively (referred to as AICD C57 and C59). An additional
g-secretase cleavage, referred to as 3 cleavage, occurs
several amino acids downstream and releases a 50 amino
acid fragment (termed AICD C50). To test whether AICD
can rescue LRP1 expression in cells deficient for either
PS or APP, we cloned AICD C50, C57, and C59 into a
retroviral vector. Infection with retrovirus expressing
AICD C50, C57, or C59 significantly suppressed LRP1
expression in MEF cells deficient for either PS1/2 or
APP/APLP2 (Figures 6C, 6D, 6F, and 6G). A reduction in
LRP1 mRNA levels was also observed when analyzed by
real-time PCR (Figures 6E and 6H). Our data indicate
that AICD is capable of rescuing the defective LRP1
expression observed in APP/APLP2-DKO and PS-DKO
Neuron
APP Regulates Brain apoE MetabolismFigure 5. g-Secretase Regulates LRP1 Expression
(A) LRP1 and LDLR expression levels were compared between WT and PS-DKO MEF cells by western blot.
(B) Densitometric analyses of western blots from quadruplicate samples indicate a significant increase in the expression of LRP1, but not LDLR, in the
absence of PS.
(C) LRP1 and LDLRmRNA levels were quantified inWT and PS-DKOMEF cells by real-time PCR. LRP1mRNA, but not LDLRmRNA, was significantly
increased in the absence of PS.
(D and E) 125I-a2M binding (D) and degradation assays (E) were performed in WT and PS-DKO MEF cells as described in Figure 2.
(F) LRP1 and LDLR expression levels were also analyzed in WT and PS-DKOmouse brains by western blot. Note the significant accumulation of APP
CTF in PS-DKO mouse brains.
(G) Densitometric analyses (n = 3) indicate a significant increase in the expression of LRP1, but not LDLR, in the absence of PS.
(H) LRP1 and LDLR mRNA levels were quantified in WT and PS-DKO mouse brain (n = 3) by real-time PCR. LRP1 mRNA, but not LDLR mRNA, was
significantly increased in the absence of PS.
(I) WTMEF cells were treated with vehicle control or g-secretase inhibitors DAPT (2 mM), DFK (100 mM), or L685,458 (1 mM) for 48 hr. Expression levels
of LRP1 and LDLR were measured by western blot.
(J) Densitometric analyses of western blots from triplicate samples indicate an increase in the expression of LRP1, but not LDLR, upon g-secretase
inhibitor treatments.
Data represent mean ± SEM; N.S., not significant; *p < 0.05, **p < 0.01.cells and strongly suggest that an AICD-dependent sig-
naling pathway is crucial for the regulation of LRP1 cellular
levels.
AICD Nuclear Signaling Inhibits LRP1
Promoter Activation
Since AICD downregulates LRP1 expression at the tran-
scriptional level and AICD has been shown to modulate
promoter function, we next tested whether LRP1 pro-
moter activity is repressed by AICD. The LRP1 promoter
was cloned into a luciferase reporter vector pGL3 (Fig-
ure 7A), and its activity was measured in BHK570 cells
and APP/APLP2-DKO MEF cells after transfection of
AICD, Fe65, or both. We found that AICD reduced LRP1
promoter activity and Fe65 further potentiated this effect
in both cell types (Figures 7B and 7C). An AICD mutantbearing a functional mutation in the 682YxNPxY motif
(Y682G, see Borg et al., 1996) lost the ability to regulate
LRP1 promoter, and Notch intracellular domain (NICD)
did not change LRP1 promoter function in this assay
(Figure 7B). To examine whether AICD binds directly to
the LRP1 promoter, we performed chromatin immunopre-
cipitation (ChIP) assay. Immunoprecipitation of mouse
brain lysates with an antibody that recognizes the APP
C-terminal domain showed that AICD associates with
the LRP1 promoter (Figures 7D and 7E). Because bio-
chemical and functional interactions among AICD, Fe65,
and Tip60 have been demonstrated (Baek et al., 2002;
Cao and Sudhof, 2001), we also analyzed the ability of an-
tibodies to Fe65 and Tip60 to immunoprecipitate the LRP1
promoter. Indeed, we found that both Fe65 and Tip60
antibodies immunoprecipitated the LRP1 promoterNeuron 56, 66–78, October 4, 2007 ª2007 Elsevier Inc. 71
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APP Regulates Brain apoE MetabolismFigure 6. AICD Rescues LRP1 Expression in the Absence of APP/APLP2 or PS1/2
(A) U87 cells were transiently transfected with plasmid constructs as indicated. LRP1 and LDLR expression levels were analyzed by western blot.
(B) Densitometric analyses of western blots from triplicate samples indicate that a forced expression of AICD and Fe65 suppressed the expression of
LRP1, but not LDLR.
(C) PS-DKOMEF cells were transiently infected with retroviral vector control or AICD C50, C57, or C59 cDNA. LRP1 and LDLR expression levels were
then analyzed by western blot and compared with those of WT MEF cells.
(D) Densitometric analyses of western blot from triplicate samples indicate that AICD expression suppressed LRP1 expression close to the levels seen
in WT MEF cells.
(E) The rescuing effect of AICD on LRP1 expression was also observed at the mRNA levels as measured by real-time PCR.
(F–H) Similar experiments to those shown in (C)–(E) were performed with APP/APLP2-DKO MEF cells.
Data represent mean ± SEM; N.S., not significant; *p < 0.05, **p < 0.01.(Figures 7D and 7E). The association of AICD, Fe65, and
Tip60 with the LRP1 promoter was specific because nor-
mal rabbit IgG failed to immunoprecipitate the LRP1 pro-
moter. In addition, APP, Fe65, and Tip60 antibodies did
not precipitate a control Notch target promoter, HES1
(Figure 7D). Further, the association of Fe65 and Tip60
with LRP1 promoter was greatly reduced in APP-KO
mouse brain (Figure 7D). These results indicate that
AICD, together with Fe65 and Tip60, bind directly to the
LRP1 promoter to suppress its activation.
AICD Rescues ApoE and Cholesterol Defects
in Cells Lacking APP/APLP2 or PS
Having demonstrated that LRP1 is a major receptor that
regulates apoE and cholesterol metabolism and that
g-secretase activity is required for APP/APLP2-mediated
regulation of LRP1 expression, we were prompted to eval-
uate potential alterations in apoE and cholesterol levels in
PS-DKO MEF cells and mouse brain. As expected, we
found that apoE levels were decreased while cholesterol72 Neuron 56, 66–78, October 4, 2007 ª2007 Elsevier Inc.levels were increased in PS-DKO MEF cells (Figures 8A
and 8C) and mouse brain (Figures 8B and 8D) when
compared to their WT controls. Normal levels of apoE
and cholesterol were found in BACE1-KO MEF cells and
BACE1-KO mouse brain (Figures 8A–8D), demonstrating
that BACE1 is not involved in apoE and cholesterol metab-
olism. Since AICD rescued LRP1 expression in MEF cells
devoid of either APP/APLP2 or PS, we then analyzed
whether forced expression of AICD could restore apoE
and cholesterol levels in these cells. Forced expression
of AICD in APP/APLP2-DKO (Figure 8E) and PS-DKO
(Figure 8F) MEF cells significantly increased apoE levels
when compared to MEF cells infected with vector alone,
albeit not to the levels observed in WT control cells.
Likewise, AICD, but not vector alone, partially restored
cholesterol levels inAPP/APLP2-DKO (Figure 8G) and PS-
DKO (Figure 8H) MEF cells. These results confirmed that
AICD-mediated control of LRP1 expression is a key
regulatory pathway in brain apoE and cholesterol
homeostasis.
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APP Regulates Brain apoE MetabolismFigure 7. AICD Binds to and Suppresses
LRP1 Promoter Activation
(A) Schematic diagram of LRP1 promoter-lucif-
erase construct.
(B) BHK570 cells were transiently cotrans-
fected with the LRP1 promoter-Luc construct
together with control vector, AICD, Fe65,
AICD/Fe65, AICD mutant (Y682G), AICD mu-
tant/Fe65, or NICD. LRP1 promoter-driven
luciferase activity was significantly decreased
by AICD and Fe65 and further by the coexpres-
sion of both, but not by an AICD mutant or
NICD.
(C) APP/APLP2-DKO MEF cells were tran-
siently cotransfected with the LRP1 pro-
moter-Luc construct together with control
vector, AICD, Fe65, or both, and the luciferase
activity was measured as in (B).
(D) ChIP assay showed that antibodies to
AICD, Fe65, and Tip60, but not control IgG,
immunoprecipitate LRP1 promoter DNA frag-
ment. Notch target HES1 promoter was used
as a negative control. The ability of anti-Fe65
and anti-Tip60 to immunoprecipitate LRP1
promoter DNA is greatly reduced in APP-KO
mouse brain.
(E) Quantitative real-time PCR analysis of LRP1
promoter DNA immunoprecipitated by control
IgG or antibodies to AICD, Fe65, and Tip60.
Data represent mean ± SEM; N.S., not signifi-
cant; *p < 0.05, **p < 0.01.DISCUSSION
It has been postulated that the amyloidogenic processing
of APP to Ab, particularly of the aggregation-prone Ab42,
plays a central role in the pathogenesis of AD (Hardy and
Selkoe, 2002). Accordingly, inhibiting APP processing to
Ab is being actively explored as a therapeutic strategy to
treat AD. Here, we described a mechanism by which the
C-terminal fragment of APP, named AICD, modulates
brain apoE and cholesterol metabolism by directly regu-
lating the expression and function of the lipoprotein recep-
tor LRP1. Knockout of APP/APLP2 or components of the
g-secretase complex significantly affected the expression
of LRP1 as well as apoE and cholesterol levels, and these
alterations were partially restored by forced expression of
AICD. We also show that AICD, together with the adaptor
proteins Fe65 and Tip60, regulates LRP1 promoter func-
tion. Our results establish a strong biological relationship
between APP processing and apoE/cholesterol metabo-
lism with significant relevance for the pathogenesis of AD.
Several biological functions for APP and its processing
products have been described (Zheng and Koo, 2006).
The notion that APP is a cell surface receptor has long
been speculated but remains unproven due to the lack
of a bona fide ligand. The function of APP is further com-
plicated by the presence of two APP-related genes,
APLP1 and APLP2 (Zheng and Koo, 2006). Deletion of
APLP2 and either APP or APLP1 results in early postnatal
lethality (Zheng and Koo, 2006), suggesting redundancybetween APLP2 and the other two family members. APP
ectodomain has been shown to participate in cell adhe-
sion, neurite outgrowth, and synaptogenesis (Zheng and
Koo, 2006). AICD, highlighted with an YxNPxY motif for
binding of an array of interacting proteins, modulates
cell migration, axonal transport, and cell signaling (Zheng
and Koo, 2006). The most relevant interacting protein is
Fe65, which modulates APP processing and AICD nuclear
translocation (Cao and Sudhof, 2001). Knockout of Fe65
and its homolog Fe65L1 results in cortical dysplasia and
compromised integrity of the pial basement membrane
(Guenette et al., 2006). Intriguingly, this phenotype closely
resembles that seen in triple-mutant mice lacking the APP
family members APP, APLP1, and APLP2 (Guenette et al.,
2006; Herms et al., 2004), strongly suggesting a common
signaling pathway that requires the function of both Fe65
and APP. Mice lacking both APP and APLP2 show defec-
tive neuromuscular synapses (Wang et al., 2005), while
mice lacking APP alone exhibit increased synapses and
associated synaptic function (Priller et al., 2006). In con-
trast, overexpression of APP in transgenic mice results
in deficits of synaptic transmission and learning (Saganich
et al., 2006) and dendritic spine abnormalities (Spires
et al., 2005). Whether some of these reported phenotypes
relate to altered apoE and cholesterol metabolism re-
ported herein requires further investigations.
Although the 34 allele of the APOE gene was discovered
as a strong genetic risk factor for late-onset AD over a de-
cade ago (Corder et al., 1993), the mechanism by whichNeuron 56, 66–78, October 4, 2007 ª2007 Elsevier Inc. 73
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APP Regulates Brain apoE MetabolismFigure 8. AICD Rescues ApoE and Cho-
lesterol Defects in Cells Deficient in PS
or APP
(A–D) ApoE (A and B) and cholesterol levels
(C and D) were measured in WT, PS-DKO,
and BACE1-KO MEF cells (A and C) and
mouse brains (B and D). ApoE levels were
decreased while cholesterol levels were in-
creased in PS-DKO but not BACE1-KO MEF
cells and mouse brain when compared to their
WT controls.
(E–H) APP/APLP2-DKO (E and G) and PS-DKO
(F and H) MEF cells were transiently infected
with retroviral vector control or AICD cDNA.
LRP1 expression levels were then analyzed
by western blot, quantified by densitometry,
and compared with those of WTMEF cells. Ex-
pression of AICD partially rescued apoE and
cholesterol levels in both APP/APLP2-DKO
and PS-DKO MEF cells.
Data represent mean ± SEM; N.S., not signifi-
cant; *p < 0.05.apoE4 contributes to AD pathogenesis is still largely un-
clear. Furthermore, whether APP and apoE regulate com-
mon biological pathways is unknown. This study provides
evidence that both APP and apoE participate in brain cho-
lesterol metabolism. Cholesterol is an essential compo-
nent of the cellular membrane and plays pivotal roles in
development and maintenance of neuronal plasticity and
function (Ledesma and Dotti, 2006). In the adult brain,
neuronal cholesterol is supplied primarily by apoE/lipo-
protein particles synthesized and secreted by glial cells
(Pfrieger, 2003; Puglielli et al., 2003). Uptake of apoE/lipo-
protein particles by neurons is mediated by lipoprotein
receptors of the LDLR family (Herz andBock, 2002). Endo-
cytosed cholesterol-containing lipoprotein particles are
hydrolyzed in neuronal lysosomes, allowing degradation
of apoE and intracellular release of free cholesterol, which
can be stored or incorporated into lipoprotein particles or
cellular membranes. A function for LRP1 in brain apoE/
cholesterol metabolism has been postulated (Pfrieger,
2003), but direct biological evidence had been lacking un-
til now. Our studies provide evidence that deletion of LRP1
in forebrain neurons of adult mice significantly alters brain
apoE and cholesterol levels. While apoE levels were in-
creased in LRP1 forebrain knockout mice, cholesterol
levels were conversely decreased. Consistent with these
findings, our previous work has shown that overexpres-
sion of an LRP1 minireceptor in the brain results in a
decrease in brain apoE level (Zerbinatti et al., 2006). To-
gether, these results strongly support a role for LRP1 in
brain apoE and cholesterol metabolism and establish
LRP1 as a neuronal receptor essential for the proper en-
docytosis and catabolism of apoE. Although the LDLR
also functions as a brain apoE receptor (Fryer et al.,
2005), our results showed that its expression is not regu-
lated by APP nor g-secretase.74 Neuron 56, 66–78, October 4, 2007 ª2007 Elsevier Inc.The role of cholesterol in AD remains controversial
(Ledesma and Dotti, 2006; Puglielli et al., 2003; Shobab
et al., 2005). Several initial studies suggested a beneficial
role of the cholesterol-lowering statins in reducing the risk
of AD, and in vitro studies have identified a role for choles-
terol in promoting Ab production. However, several recent
studies do not support these conclusions (Shobab et al.,
2005). Additionally, mice treated with lovastatin, the
most brain-penetrant statin currently available, exhibit
increased Ab production and amyloid plaque deposition
(Park et al., 2003). Furthermore, neuronal membrane
cholesterol loss was recently found to enhance Ab
production (Abad-Rodriguez et al., 2004). Interestingly,
a significant reduction of brain cholesterol in AD patients
was observed, particularly in areas loaded with amyloid
plaques (Ledesma et al., 2003). These findings suggest
that loss of neuronal cholesterol may contribute to synap-
tic dysfunction and excess Ab production in AD. Because
LRP1 levels are also significantly reduced in AD (Kang
et al., 2000), we can speculate that decreased LRP1 levels
in AD are directly responsible for cholesterol loss and
related synaptic dysfunction. Accordingly, g-secretase
inhibitor treatment, a strategy actively explored for AD
therapy, will likely increase the expression and function
of LRP1 in cholesterol metabolism, which could in turn
support synaptic integrity and function. Because LRP1
also has a role in Ab clearance by neurons (Zerbinatti
and Bu, 2005) and across the blood-brain barrier (Deane
et al., 2004), restoring LRP1 expression and function in
the AD brain could be explored independently as a thera-
peutic strategy to treat AD. Interestingly, the expression of
another member of the LDLR family, SorLA, that regulates
APP trafficking and processing to Ab is also decreased
in AD brains (Andersen et al., 2005; Rogaeva et al., 2007),
and inherited variants in the SorLA gene, SORL1, are
Neuron
APP Regulates Brain apoE Metabolismassociated with late-onset AD (Rogaeva et al., 2007). To-
gether, these studies point to multiple pathways by which
LDLR familymembersplay roles in thepathogenesis ofAD.
Our results reveal a role for g-secretase-dependent
APP processing in the regulation of brain cholesterol
levels via transcriptional repression of LRP1. Presenilin-
dependent cleavage of APP results in the release of
AICD, which has been shown to interact with Fe65 and
Tip60 and has been suggested to function in nuclear sig-
naling (Baek et al., 2002; Cao and Sudhof, 2001). Subse-
quent work by Cao and Sudhof (Cao and Sudhof, 2004)
demonstrated that nuclear translocation of AICD may be
dispensable, raising the possibility that AICD could func-
tion by modulating activation of Fe65 rather than function-
ing as a transcriptional regulator itself. Several studies
have reported putative target genes differentially
regulated by an AICD-containing complex, including the
prostate cancer antimetastasis gene KAI1 (Baek et al.,
2002), APP, GSK3b (Von Rotz et al., 2004), neprilysin
(Pardossi-Piquard et al., 2005), regulators of actin dynam-
ics (Muller et al., 2007), and the EGF receptor (Zhang et al.,
2007). However, the exact role of AICD in transcriptional
regulation of target genes remains controversial (Hebert
et al., 2006; Chen and Selkoe, 2007; Pardossi-Piquard
et al., 2007). Specifically, work by De Strooper and
colleagues (Hebert et al., 2006) has shown that expression
of several previously defined AICD target genes was at
best indirectly and weakly affected by APP processing.
Further, the role of AICD in regulating neprilysin expres-
sion (Pardossi-Piquard et al., 2005, 2007) was not repro-
duced by another report (Chen and Selkoe, 2007). Finally,
a recent study has shown that secreted APP ectodomain
APPsa is sufficient to rescue several anatomical, behav-
ioral, and electrophysiological abnormalities seen in
APP-KO mice (Ring et al., 2007). The discrepancy in
AICD function could be due to different experimental sys-
tems and/or approaches (Herz, 2007). In line with a biolog-
ical function of AICD, our results provide direct evidence
that AICD binds to the LRP1 promoter and regulates its
transcriptional function. Although our studies do not
exclude the possibility that APP itself or other APP pro-
cessing products (e.g., soluble APP and Ab) may also
regulate LRP1 expression and function, our findings that
LRP1 expression and apoE/cholesterol metabolism are
unchanged in BACE1 knockout mice argues against
a role for Ab in regulating LRP1 expression. Supporting
an Ab-independent function of g-secretase, recent work
has demonstrated that a complete loss of presenilin func-
tion in the forebrain leads to memory deficits, synaptic
dysfunction, and neurodegeneration without generation
of amyloid plaques (Saura et al., 2004). These results
suggest that at least some of the neurodegenerative pa-
thology seen in AD might result from partial loss of g-sec-
retase activity or AICD nuclear signaling functions inde-
pendent of Ab production (Shen and Kelleher, 2007). It is
interesting to note that a recent study demonstrates
a role for Ab in regulating cholesterol biosynthesis and
sphingomyelin degradation (Grimm et al., 2005). BecauseAICD did not completely restore apoE and cholesterol
levels inPS-DKO cells, it is possible that other g-secretase
cleavage products may also regulate apoE/cholesterol
metabolism via LRP1-dependent and/or independent
mechanisms. Regulation of cholesterol synthesis by Ab,
as well as AICD-mediated modulation of LRP1 expres-
sion, are likely to be key events in the proper maintenance
of brain cholesterol levels.
In summary, this study uncovers a biological function of
APP in modulating brain apoE and cholesterol homeosta-
sis. We further demonstrate an important role of the APP
processing product AICD in modulating the promoter
activity of LRP1, an essential lipoprotein receptor for brain
apoE and cholesterol metabolism. Our results provide
important insights into APP biological function and its
potential implications for neuronal dysfunction in AD and
may lead to the design of better therapeutic strategies to
treat this devastating disease.
EXPERIMENTAL PROCEDURES
Materials
Human recombinant RAP was expressed in a glutathione S-transfer-
ase expression vector and isolated as described previously
(Bu et al., 1993). All tissue culture media and serum were from Sigma.
Anti-APP C-terminal antibody was purchased from Invitrogen; anti-
Fe65 was from Abcam; anti-Tip60 was from Calbiochem; anti-actin
was from Sigma; and anti-NeuN was from Chemicon. In-house
anti-LRP1 and anti-LDLR antibodies have been described previously
(Bu et al., 1995; Li et al., 2005; Zerbinatti et al., 2004). Peroxidase-la-
beled anti-mouse antibody and ECL systemwere fromGE Healthcare.
Carrier-free Na125I was purchased from Perkin Elmer Lifescience. The
g-secretase inhibitors L685,458 andDAPTwere fromCalbiochem, and
DFK167 was from Enzyme Systems.
Animals and Tissue Preparation
LRP1 forebrain knockout mice were generated by breeding the LRP1
loxP mice (Rohlmann et al., 1998) with a-calcium-calmodulin-depen-
dent kinase II-driven Cre recombinase mice (Tsien et al., 1996). Litter-
mates of LRP1 forebrain knockout (LRP1flox+/+, Cre+/) or WT controls
(LRP1flox+/+, Cre/) at 11 months of age were used for western blot-
ting, immunofluorescence staining, and apoE/cholesterol assays.
APP-KO, APP/APLP2-DKO, and WT littermate control mice have
been described previously and were used within 24 hr after birth due
to potential lethality of the APP/APLP2-DKO mice. APP-KO mice
were also analyzed at 4 months of age. PS1/2-DKO mice were gener-
ated by Cre-lox conditional deletion of the PS1 gene in forebrain of the
PS2-KO mice (Feng et al., 2004) and were used at 4 months of age.
BACE1-KO mice (Luo et al., 2001) were described in previous work
and were used at 2 months of age. Animals were perfused with
PBS-heparin (3 units/ml), and brain tissues were dissected and kept
frozen at 80C until further analysis. All animal procedures were
approved by the Animal Study Committee at Washington University
School of Medicine and in accordance with the regulations of the
American Association for the Accreditation of Laboratory Animal Care.
Reverse Transcriptase Real-Time PCR
Total RNA was isolated from tissues or cells using the SV Total RNA
Isolation System (Promega) and subjected to DNase I digestion to
remove contaminating genomic DNA. Total RNA was dissolved in
nuclease-free water and stored at 80C. Reverse transcription was
performed using a SuperScript II RNase H-reverse transcriptase (Invi-
trogen), and the reaction mix was subjected to quantitative real-time
PCR to detect levels of the corresponding actin, LRP1, or LDLR. TheNeuron 56, 66–78, October 4, 2007 ª2007 Elsevier Inc. 75
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gene amplification. The relative levels of expression were quantified
and analyzed by using Bio-Rad iCycler iQ software. The real-time value
for each sample was averaged and compared using the CT method,
where the amount of target RNA (2DDCT) was normalized to the
endogenous actin reference (DCT) and related to the amount of target
gene in tissue cells, which was set as the calibrator at 1.0.
ApoE ELISA
The sandwich ELISA for mouse apoE has been described previously
(Wahrle et al., 2004). Briefly, 96-well plates were coated overnight
with apoE antibody (WU E4), washed with PBS, blocked with 1%
milk in PBS, and then washed again. Cells or brain samples were son-
icated in 5 M guanidine HCl with 13 Complete protease inhibitor mix-
ture (Roche Applied Science), debris was pelleted by centrifugation at
10,000 3 g, and the supernatant was diluted in 0.1% BSA, 0.025%
Tween 20 in PBS. Following sample incubation, the plate was washed,
and 3 mg/well of biotinylated goat anti-apoE (Calbiochem) was added.
After incubation with the secondary antibody, the plate was washed,
and poly-horseradish peroxidase streptavidin (Pierce) was added at
1:6000 dilution and incubated. The plate was then washed, developed
with tetramethylbenzidine (Sigma), and read at 650 nm with a Biotek
600 plate reader (Bio-Tek Instruments).
Cholesterol Analyses
Cells or brain samples were prepared for cholesterol analysis by
sonication in PBS with 13 Complete protease inhibitor mixture. The
homogenized whole-cell or brain suspension was then subjected to
enzymatic analysis for total cholesterol using the Amplex Red Choles-
terol Kit (Invitrogen) (Wahrle et al., 2004).
Immunofluorescence Staining
Frozen tissue sections were blocked with 0.1% Tween 20, 5% BSA
in PBS for 30 min and stained for 2 hr at room temperature with anti-
LRP1 antibody. Primary antibody was then visualized using Alexa
488-labeled goat anti-mouse secondary antibody (Invitrogen). Neu-
rons were counterstained with anti-NeuN (Calbiochem) and Alexa
633-labeled secondary antibody (Invitrogen). Fluorescent images
were captured with a confocal microscope (Olympus Fluoview 500).
Chromatin Immunoprecipitation
ChIP assays were performed using a chromatin immunoprecipitation
(ChIP) assay kit (Upstate) according to the manufacturer’s instructions
with minor modifications. Briefly, brain tissue fromWT C57BL/6J mice
were minced into small pieces with a razor and 1% formaldehyde was
added directly to the tissue mixture to crosslink proteins to DNA. Tis-
sue was then lysed in SDS lysis buffer and sonicated to shear DNA to
a size range of 200–1000 bp. After centrifugation, the supernatant was
diluted 10-fold in ChIP dilution buffer and incubated overnight at 4C
with anti-APP, anti-Fe65, anti-Tip60, or normal rabbit IgG. Protein A-
agarose beads were used to immunoprecipitate the antibody/pro-
tein/DNA complexes. After washing, the complex was incubated at
65C for 4 hr to reverse the protein/DNA crosslinks. The DNA was
then purified using PCRPurification kit (QIAGEN) and used as template
for PCR amplification. LRP1-F (50-TCGGGTGTCCCTGTTTAC-30) and
LRP1-R (50-GAAAGCGGTCCAAGAGTG-30 ) primers were used to am-
plify the LRP1 promoter by RT-PCR. LRP1-F (50-GGGAGCCTGAAA
TCCTAGAG-30) and LRP1-R (50-GGAAAGCGGTCCAAGAGTG-30)
primers were used to amplify LRP1 promoter by real-time PCR.
Primers for HES1 promoter amplification are as follows: HES1-F, 50-C
GTGTCTCTTCCTCCCATTG-30; HES1-R, 50- GATCCAGTGTGATCC
GCAGG-30. PCR products were resolved on 2% agarose gels and
visualized by ethidium bromide staining.
Luciferase Assay
BHK570 cells orMEFAPP/APLP2-DKO cells were transfectedwith the
appropriate cDNAs: empty vector (pGL3-luc), LRP1 promoter-luc,76 Neuron 56, 66–78, October 4, 2007 ª2007 Elsevier Inc.AICD, and/or Fe65. A b-gal reporter cDNA was cotransfected to nor-
malize data for transfection efficiency. Twenty-four hours after trans-
fection, cells were rinsed, gently scraped into PBS (pH 7.4), and
pelleted. Cells were then lysed in lysis buffer, and the luciferase activity
and b-gal activity were measured by the Luciferase Assay System and
b-gal Assay System following the manufacturer’s instructions
(Promega).
Statistical Analysis
All quantified data represent an average of at least triplicate samples.
Error bars represent standard error of the mean. Statistical signifi-
cance was determined by Student’s t test, and p < 0.05 was consid-
ered significant.
Supplemental Data
The Supplemental Data for this article can be found online at http://
www.neuron.org/cgi/content/full/56/1/66/DC1/.
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